tbuckley/cabot-search huggingface dataset:
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
Authors: Gabriel Morin, Caroline Degrugillier-Chopinet, Marie Vincent, Antoine Fraissenon, Hélène Aubert, Célia Chapelle, Clément Hoguin, François Dubos, Benoit Catteau, Florence Petit, Aurélie Mezel, Olivia Domanski, Guillaume Herbreteau, Marie Alesandrini, Nathalie Boddaert, Nathalie Boutry, Christine Broissand, Tianxiang Kevin Han, Fabrice Branle, Sabine Sarnacki, Thomas Blanc, Laurent Guibaud, Guillaume Canaud
Journal: The Journal of Experimental Medicine (2022)

PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.
Book Review Technic of Electrotherapy and Its Physical and Physiological Basis. By Stafford L. Osborne, M.S., Ph.D., and Harold J. Holmquest, B.S., B.S. (M.E.). 8°, cloth, 780 pp., with 240 illustrations and 72 tables. Springfield, Illinois: Charles C Thomas, 1944. $7.50.
Journal: New England Journal of Medicine (1945)
I.—<i>L'Hérédité Morbide et la Dégénérescence. dans leurs Rapports avec la Responsabilité des Aetes.</i> Par le Dr. Victor Parant. <i>Morbid heredity and degeneration in their relation to responsibility.</i>) Extr. from <i>Memoirs of Acad. des Sciences,</i> Touloumse, 1890
Authors: H. M. B.
Journal: American Journal of Psychiatry (1890)
Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time
Authors: Monica Tang, Brett M. Elicker, Travis Henry, David S. Gierada, Mark L. Schiebler, Brendan K. Huang, Michael C. Peters, Mario Castro, Eric A. Hoffman, Sean B. Fain, Samuel Y. Ash, Jiwoong Choi, Chase Hall, Brenda R. Phillips, David T. Mauger, Loren C. Denlinger, Nizar N. Jarjour, Elliot Israel, Wanda Phipatanakul, Bruce D. Levy, Sally E. Wenzel, Eugene R. Bleecker, Prescott G. Woodruff, John V. Fahy, Eleanor M. Dunican
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Cross-sectional analysis of mucus plugs in computed tomography (CT) lung scans in the Severe Asthma Research Program (SARP)-3 showed a high mucus plug phenotype.
GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition
Authors: Audrys G. Pauza, Pratik Thakkar, Tatjana Tasic, Igor Felippe, Paul Bishop, Michael P. Greenwood, Kristina Rysevaite-Kyguoliene, Julia Ast, Johannes Broichhagen, David J. Hodson, Helio C. Salgado, Dainius H. Pauza, Nina Japundzic-Zigon, Julian F.R. Paton, David Murphy
Journal: Circulation Research (2022)

Background: Aberrant sympathetic nerve activity exacerbates cardiovascular risk in hypertension and diabetes, which are common comorbidities, yet clinically sympathetic nerve activity remains poorly controlled. The hypertensive diabetic state is associated with increased reflex sensitivity and tonic drive from the peripheral chemoreceptors, the cause of which is unknown. We have previously shown hypertension to be critically dependent on the carotid body (CB) input in spontaneously hypertensive rat, a model that also exhibits a number of diabetic traits. CB overstimulation by insulin and leptin has been similarly implicated in the development of increased sympathetic nerve activity in metabolic syndrome and obesity. Thus, we hypothesized that in hypertensive diabetic state (spontaneously hypertensive rat), the CB is sensitized by altered metabolic signaling causing excessive sympathetic activity levels and dysfunctional reflex regulation. Methods: Using a hypothesis-free RNA-seq approach, we investigated potential molecular targets implicated in energy metabolism mediating CB sensitization and its regulation of sympathetic outflow in experimental hypertension. Identified targets were characterized using molecular and functional techniques assessing peripheral chemoreflex sensitivity in situ and in vivo. Results: We discovered GLP1R (glucagon-like peptide-1 receptor) expression in the CBs of rat and human and showed that its decreased expression is linked to sympathetic hyperactivity in rats with cardiometabolic disease. We demonstrate GLP1R to be localized to CB chemosensory cells, while targeted administration of GLP1R agonist to the CB lowered its basal discharge and attenuated chemoreflex-evoked blood pressure and sympathetic responses. Importantly, hyperglycemia-induced peripheral chemoreflex sensitization and associated basal sympathetic overactivity were abolished by GLP1R activation in the CB suggesting a role in a homeostatic response to high blood glucose. Conclusions: We show that GLP1 (glucagon-like peptide-1) modulates the peripheral chemoreflex acting on the CB, supporting this organ as a multimodal receptor. Our findings pinpoint CBs as potential targets for ameliorating excessive sympathetic activity using GLP1R agonists in the hypertensive-diabetic condition.
Clip-with-line traction suture method with adaptation of the mucosal flap in a large transmural defect after submucosal tunneling endoscopic resection of a submucosal tumor at the esophagogastric junction
Authors: Annalisa Cappello, Sofia Xavier, Horst Neuhaus, Torsten Beyna, Christian Gerges
Journal: Endoscopy (2022)

Submucosal tunneling endoscopic resection (STER) [1] is a demanding technique that can potentially lead to serious complications [2] [3]. A 51-year-old patient with solid food dysphagia underwent an esophagogastroduodenoscopy, which showed a subepithelial mass just below the esophagogastric junction (EGJ). Endoscopic ultrasound confirmed a well-demarcated 30 × 24 mm subepithelial mass attached to the muscularis propria, predominantly hypoechogenic but with some hyperechogenic foci.
Books Received
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap
Authors: Dvora L Joseph Davey, Linda-Gail Bekker, Elizabeth A Bukusi, Benjamin H Chi, Sinead Delany-Moretlwe, Ameena Goga, Anne Drapkin Lyerly, Nyaradzo M Mgodi, Nelly Mugo, Landon Myer, Lisa M Noguchi, Lynda Stranix-Chibanda, Catherine Slack, Jillian Pintye
Journal: The Lancet HIV (2022)
BELGIUM
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Addressing Stigma to Provide Quality Care to People Who Use Drugs
Authors: Shoshana Aronowitz, Zachary F. Meisel
Journal: JAMA Network Open (2022)

Alene Kennedy-Hendricks, PhD; Emma E. McGinty, PhD, MS; Amber Summers, PhD; Susan Krenn, BA; Michael I. Fingerhood, MD; Colleen L. Barry, PhD, MPP
Human Antibodies for Viral Infections
Authors: James E. Crowe
Journal: Annual Review of Immunology (2022)

Antibodies have been used to prevent or treat viral infections since the nineteenth century, but the full potential to use passive immunization for infectious diseases has yet to be realized. The advent of efficient methods for isolating broad and potently neutralizing human monoclonal antibodies is enabling us to develop antibodies with unprecedented activities. The discovery of IgG Fc region modifications that extend antibody half-life in humans to three months or more suggests that antibodies could become the principal tool with which we manage future viral epidemics. Antibodies for members of most virus families that cause severe disease in humans have been isolated, and many of them are in clinical development, an area that has accelerated during the effort to prevent or treat COVID-19 (coronavirus disease 2019). Broad and potently neutralizing antibodies are also important research reagents for identification of protective epitopes that can be engineered into active vaccines through structure-based reverse vaccinology.
Abstracts of the 25th Annual Northeast Regional Scientific Meeting of the Greater New York and New England Chapters of the Society of Nuclear Medicine
Journal: Clinical Nuclear Medicine (2012)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Online First Collections ACNM MeetingsCMECommunication in OrganizationCOVID-19Feedback and RewardsFrom the American College of Nuclear MedicineHighly Cited and Frequently Read ArticlesPlanning and Conducting Meetings EffectivelyQuality and Safety in Health CareRecruitment of New PhysiciansTips for Giving a Memorable PresentationTips for LeadersTips for Physicians in Getting the Right Job ACNM ArticlesACNM Website For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor Permissions Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
Medical News.
Journal: JAMA (1903)

<h3>CONNECTICUT.</h3><h3>November Infectious Diseases.</h3> —During November one case of smallpox was reported; 643 cases of measles, with 2 deaths; 132 cases of scarlet fever, with one death; 182 cases of diphtheria, with 4 deaths; 86 cases of whooping cough, with one death; 79 cases of typhoid fever, with one death, and 29 cases of consumption, with 20 deaths. <h3>National Guard Changes Suggested.</h3> —At an informal meeting of the surgeons of the Connecticut National Guard, New Haven, December 9, it was decided to recommend to the military authorities that a medical department independent of the regimental medical officers be formed, that an additional surgeon be added to each regiment, and that the hospital corps consist of ten men to a regiment. <h3>November Deaths.</h3> —During November 1,167 deaths were reported, 43 more than in the previous month, 84 more than in November, 1902, and 109 more than the average for the last
Gene Regulatory Circuits in Innate and Adaptive Immune Cells
Authors: Ankita Saini, Hazem E. Ghoneim, Chan-Wang Jerry Lio, Patrick L. Collins, Eugene M. Oltz
Journal: Annual Review of Immunology (2022)

Cell identity and function largely rely on the programming of transcriptomes during development and differentiation. Signature gene expression programs are orchestrated by regulatory circuits consisting of cis-acting promoters and enhancers, which respond to a plethora of cues via the action of transcription factors. In turn, transcription factors direct epigenetic modifications to revise chromatin landscapes, and drive contacts between distal promoter-enhancer combinations. In immune cells, regulatory circuits for effector genes are especially complex and flexible, utilizing distinct sets of transcription factors and enhancers, depending on the cues each cell type receives during an infection, after sensing cellular damage, or upon encountering a tumor. Here, we review major players in the coordination of gene regulatory programs within innate and adaptive immune cells, as well as integrative omics approaches that can be leveraged to decipher their underlying circuitry.
Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association Between Use of β-Blockers and Prostate Cancer–specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-risk or Metastatic Disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.
Authors: Krishnan Bhaskaran, Bernard Rachet, Stephen Evans, Liam Smeeth
Journal: European Urology (2013)
Dronedarone in High-Risk Permanent Atrial Fibrillation
Authors: Stuart J. Connolly, A. John Camm, Jonathan L. Halperin, Campbell Joyner, Marco Alings, John Amerena, Dan Atar, Álvaro Avezum, Per Blomström, Martin Borggrefe, Andrzej Budaj, Shih-Ann Chen, Chi Keong Ching, Patrick Commerford, Antonio Dans, Jean-Marc Davy, Etienne Delacrétaz, Giuseppe Di Pasquale, Rafael Diaz, Paul Dorian, Greg Flaker, Sergey Golitsyn, Antonio Gonzalez-Hermosillo, Christopher B. Granger, Hein Heidbüchel, Josef Kautzner, June Soo Kim, Fernando Lanas, Basil S. Lewis, Jose L. Merino, Carlos Morillo, Jan Murin, Calambur Narasimhan, Ernesto Paolasso, Alexander Parkhomenko, Nicholas S. Peters, Kui-Hian Sim, Martin K. Stiles, Supachai Tanomsup, Lauri Toivonen, János Tomcsányi, Christian Torp-Pedersen, Hung-Fat Tse, Panos Vardas, Dragos Vinereanu, Denis Xavier, Jun Zhu, Jun-Ren Zhu, Lydie Baret-Cormel, Estelle Weinling, Christoph Staiger, Salim Yusuf, Susan Chrolavicius, Rizwan Afzal, Stefan H. Hohnloser
Journal: New England Journal of Medicine (2011)

Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation.We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death.After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02).Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.).
The Nod
Authors: Kimberly D. Manning
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Racial and Ethnic Differences in Food Allergy Reactions and Treatment Outcomes
Authors: Neil Thivalapill, Lucy Bilaver, Jialing Jiang, Khalid Ibrahim, Christopher Warren, Ososese Enaholo, Haley Hultquist, Davida Kay, Jennifer Long, Pamela Newmark, Sai Nimmagadda, Jacqueline Pongracic, Stephanie Shigo, Eileen Vincent, Mark Wlodarski, Amal Assa'ad, Annika Chura, Aame Andy-Nweye, Susan Fox, Mahboobeh Mahdavinia, Mary Tobin, Amaziah Coleman, Linda Herbert, Izeris Ortiz-Rodriguez, Hemant Sharma, Andrea Pappalardo, Ruchi Gupta
Journal: Journal of Allergy and Clinical Immunology (2022)
Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293
Authors: Chen Dong, Sung-Lang Chen, Wen-Wei Sung
Journal: European Urology (2022)
A Tyrosine Adsorbed Modified Grass Allergen + MPL SCIT Demonstrates Clinically Improvement in Combined Symptom and Medication Score in Subjects with Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis
Authors: Lawrence DuBuske, Stefan Zielen, Jonathan Bernstein, Uwe Berger, Markus Berger, Mandy Cuevas, David Cypcar, Annette Fuhr-Horst, William Greisner, Margret Jandl, Sabine Laßmann, Margitta Worm, Jonathan Matz, Ellen Sher, Chris Smith, Gary Steven, Kemi Oluwayi, Marion Seybold, Matthias Kramer, Murray Skinner, Pieter -Jan de Kam
Journal: Journal of Allergy and Clinical Immunology (2022)
A trial of clonidine to stop smoking
Authors: Steven A. Ornish
Journal: JAMA (1990)

<h3>To the Editor.—</h3> I have significant concerns about the design and data analysis in the study by Franks et al<sup>1</sup>and their conclusions on oral clonidine and smoking cessation, published in the December 1 issue of<i>JAMA</i>. Franks et al make the point that other studies that excluded subjects who were still smoking (even a few cigarettes per day) may have introduced a bias. Yet Franks et al themselves excluded and failed to report the data of almost 80% of their subjects (71 of 92 subjects excluded in the experimental group and 74 of 93 subjects excluded in the placebo group). The exclusion of these subjects introduces a significant selection bias—those subjects excluded who continued to smoke a few cigarettes per day may have been the most addicted to nicotine, may have had the highest severity of withdrawal symptoms, and may have been the subjects most likely to benefit
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential
Authors: Lina Gao, Yun Zhang, Keenan Sterling, Weihong Song
Journal: Translational Neurodegeneration (2022)

Abstract Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that are known to arise as the disease progresses. A growing body of evidence suggests that pathological alterations to neuronal circuits and synapses may provide a mechanistic link between amyloid β (Aβ) and tau pathology and thus may serve as an obligatory relay of the cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play an important role in maintaining synaptic plasticity in learning and memory. Considering AD as a synaptic disorder, BDNF has attracted increasing attention as a potential diagnostic biomarker and a therapeutical molecule for AD. Although depletion of BDNF has been linked with Aβ accumulation, tau phosphorylation, neuroinflammation and neuronal apoptosis, the exact mechanisms underlying the effect of impaired BDNF signaling on AD are still unknown. Here, we present an overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling. We then discuss the role of BDNF in AD and the potential of BDNF-targeting therapeutics for AD.
Prodrug Polymeric Nanoconjugates Encapsulating Gold Nanoparticles for Enhanced X‐Ray Radiation Therapy in Breast Cancer (Adv. Healthcare Mater. 3/2022)
Authors: Hamed Nosrati, Farzad Seidi, Ali Hosseinmirzaei, Navid Mousazadeh, Ali Mohammadi, Mohammadreza Ghaffarlou, Hossein Danafar, João Conde, Ali Sharafi
Journal: Advanced Healthcare Materials (2022)

Gold Nanoparticles In article number 2102321 by Farzad Seidi, João Conde, Ali Sharafi, and co-workers, in vivo X-ray radiation using prodrug polymeric nanoconjugates encapsulating gold nanoparticles impair the proliferation of breast cancer cells, blocking the ability of a single cancer cell to grow into a colony, and therefore forming tumors.
Predicting the long‐term course of atopic dermatitis in childhood
Journal: British Journal of Dermatology (2022)

Journal Article Predicting the long‐term course of atopic dermatitis in childhood Get access British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Page e92, https://doi.org/10.1111/bjd.20920 Published: 01 February 2022